Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Operating Leases (2022 - 2025)

Biodesix (BDSX) has disclosed Operating Leases for 4 consecutive years, with $24.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases fell 3.18% year-over-year to $24.0 million, compared with a TTM value of $24.0 million through Dec 2025, down 3.18%, and an annual FY2025 reading of $24.0 million, down 3.18% over the prior year.
  • Operating Leases was $24.0 million for Q4 2025 at Biodesix, down from $24.4 million in the prior quarter.
  • Across five years, Operating Leases topped out at $25.5 million in Q2 2024 and bottomed at $1.2 million in Q1 2022.
  • Average Operating Leases over 4 years is $18.2 million, with a median of $24.3 million recorded in 2025.
  • The sharpest move saw Operating Leases skyrocketed 922.85% in 2023, then fell 5.37% in 2025.
  • Year by year, Operating Leases stood at $5.3 million in 2022, then skyrocketed by 378.93% to $25.2 million in 2023, then dropped by 1.33% to $24.8 million in 2024, then dropped by 3.18% to $24.0 million in 2025.
  • Business Quant data shows Operating Leases for BDSX at $24.0 million in Q4 2025, $24.4 million in Q3 2025, and $24.1 million in Q2 2025.